A prospective evaluation of Johnson & Johnson COVID-19 vaccine on glycemic biomarkers in type 2 diabetes mellitus in Ethiopia

TL;DR

This study examines how the Johnson & Johnson COVID-19 vaccine affects blood sugar levels in people with type 2 diabetes in Ethiopia.

Contribution

The study provides new insights into the effects of the Johnson & Johnson vaccine on glycemic control in a T2DM population.

Findings

Vaccinated individuals showed temporary increases in random blood sugar levels three months post-vaccination.

Hemoglobin A1c levels increased gradually over time in vaccinated individuals.

Younger individuals and females experienced greater glycemic variability.

Abstract

People living with Type 2 Diabetes Mellitus (T2DM) face a heightened risk of experiencing severe complications from COVID-19, underscoring the importance of vaccination. Nonetheless, the impact of COVID-19 vaccines—especially the Johnson & Johnson (Ad26.COV2.S) vaccine—on glucose regulation has not been fully elucidated. This study evaluates the impact of vaccination on glycemic parameters, including Random Blood Sugar (RBS) and Hemoglobin A1c (HbA1c), and identifies factors influencing glycemic variability.

Between May 2023 and June 2024, a prospective cohort study was carried out at Adama Hospital Medical College in Ethiopia. Adults diagnosed with Type 2 Diabetes Mellitus were divided into two cohorts based on vaccination status: those who received the vaccine and those who did not. Glycemic parameters were recorded at baseline and subsequently at three-month intervals—specifically at 3, 6, 9, and 12 months following vaccination. To evaluate trends over time and identify influencing factors, including demographic and clinical variables, longitudinal data were analyzed using Generalized Estimating Equations (GEE).

Vaccinated individuals exhibited transient elevations in RBS, peaking at three months post-vaccination before stabilizing. In contrast, HbA1c levels demonstrated a gradual increase over time. Greater glycemic variability was observed in younger individuals and females. The primary determinants of variations in glycemic levels were vaccination status, duration following immunization, and demographic characteristics. In contrast, diabetes treatments and lifestyle-related factors showed only a limited influence.

The Johnson & Johnson COVID-19 vaccine was associated with short-term RBS fluctuations and a sustained increase in HbA1c levels in T2DM patients. These findings highlight the need for personalized glycemic monitoring post-vaccination. Despite these metabolic variations, the vaccine’s protective role against severe COVID-19 outweighs transient glycemic disturbances. Incorporating vaccination efforts into comprehensive diabetes management is crucial, and additional studies are warranted to investigate the underlying biological mechanisms.

Figures